424 related articles for article (PubMed ID: 31878223)
1. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
2. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
3. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
4. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
6. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
7. Dragging ras back in the ring.
Stephen AG; Esposito D; Bagni RK; McCormick F
Cancer Cell; 2014 Mar; 25(3):272-81. PubMed ID: 24651010
[TBL] [Abstract][Full Text] [Related]
8. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.
Shetu SA; Bandyopadhyay D
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409064
[TBL] [Abstract][Full Text] [Related]
11. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
Kattan WE; Hancock JF
Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
[TBL] [Abstract][Full Text] [Related]
12. The RAS-Effector Interaction as a Drug Target.
Keeton AB; Salter EA; Piazza GA
Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
[TBL] [Abstract][Full Text] [Related]
13. Crystallographic Studies of KRAS in Complex with Small Molecules and RAS-Binding Proteins.
Chan AH; Simanshu DK
Methods Mol Biol; 2024; 2797():47-65. PubMed ID: 38570452
[TBL] [Abstract][Full Text] [Related]
14. Climbing RAS, the everest of oncogenes.
Russo M; Di Nicolantonio F; Bardelli A
Cancer Discov; 2014 Jan; 4(1):19-21. PubMed ID: 24402942
[TBL] [Abstract][Full Text] [Related]
15. Understanding and drugging RAS: 40 years to break the tip of the iceberg.
Brady DC; Hmeljak J; Dar AC
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35244677
[TBL] [Abstract][Full Text] [Related]
16. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
17. Ras and exosome signaling.
Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
Okumura S; Jänne PA
Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
[TBL] [Abstract][Full Text] [Related]
19. How to make an undruggable enzyme druggable: lessons from ras proteins.
Sayyed-Ahmad A; Gorfe AA
Adv Protein Chem Struct Biol; 2020; 122():181-202. PubMed ID: 32951811
[TBL] [Abstract][Full Text] [Related]
20. New druggable targets in the Ras pathway?
Matallanas D; Crespo P
Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
